Drug-drug interaction potential of SH-1028, a third-generation EGFR-TKI: in vitro and clinical trials

Li, XL; Liu, YY; Zhu, MH; He, CX; Xu, YY; Ding, JX; Wang, Y; Shan, RF; Liu, BY; Ding, YZ; Xie, J; Zhou, H; Wang, ZQ; Liu, YY

Liu, YY (通讯作者)，Bengbu Med Coll, Clin Trial Ctr, Affiliated Hosp 1, Bengbu 233009, Peoples R China.;Liu, YY (通讯作者)，Bengbu Med Coll, Sch Pharm, Bengbu 233030, Peoples R China.

INVESTIGATIONAL NEW DRUGS, 2023; 41 (3): 453

Abstract

SH-1028 is an irreversible third-generation EGFR tyrosine kinase inhibitor (EGFR-TKI) for the treatment of locally advanced or metastatic non-small ce......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索